Dermal Cell News Volume 8.16 | May 9 2022

    By
    Bob
    -
    0
    52






    2022-05-09 | DCN 8.16


    Dermal Cell News by STEMCELL Technologies
    Vol. 8.16 – 9 May, 2022
    TOP STORY

    MrgprF Acts as a Tumor Suppressor in Cutaneous Melanoma by Restraining PI3K/Akt Signaling

    Scientists identified that MrgprF, a MAS-related GPR family member, was decreased in cutaneous melanoma (CM) tissues and cell lines due to hypermethylation of its promoter region, and showed that patients with CM expressing high levels of MrgprF exhibited an improved clinical outcome.
    [Signal Transduction and Targeted Therapy]

    Full Article
    Stay up-to-date with the latest stem cell research by listening to the Stem Cell Podcast!
    PUBLICATIONSRanked by the impact factor of the journal

    Age-Related Decrease in Responsiveness of CD271-Positive Skin Stem Cells to Growth Factors

    Investigators focused on epidermal growth factor/epidermal growth factor receptor signaling and fibroblast growth factor-2/fibroblast growth factor receptor signaling and analyzed the age-related changes.
    [Experimental Dermatology]

    Abstract

    Chronic Arsenic Exposure Suppresses ATM Pathway Activation in Human Keratinocytes

    Researchers reported that phosphorylation of ataxia telengectasia mutated (ATM) protein at a critical site important for DNA damage response signaling, and downstream CHEK2 activation, were significantly reduced in two human keratinocyte lines as a result of chronic inorganic arsenic exposure.
    [Toxicology and Applied Pharmacology]

    AbstractGraphical Abstract

    Large-Scale Isolation of Functional Dermal Papilla Cells Using Novel Surface Marker LEPR

    The authors systematically screened for the surface proteins specifically expressed in skin dermal papilla using mRNA expression databases.
    [Cytometry Part A]

    Abstract

    Chrna5 Is Overexpressed in Psoriasis Patients and Promotes Psoriasis-Like Inflammation in Mouse Models

    Scientists examined the role of cholinergic receptor nicotinic subunit alpha-5 (Chrna5) in psoriasis development and pathogenesis. Human keratinocytes were analyzed, and silencing Chrna5 inhibited keratinocyte proliferation and migration.
    [Journal of Investigative Dermatology]

    Abstract

    Transglutaminase 3 Attenuates Skin Inflammation in Psoriasis by Inhibiting NF-κB Activation via P-STAT3–TET3 Signaling

    Researchers showed that transglutaminase 3 expression was increased in skin lesions of psoriasis patients and a mouse model of imiquimod-induced psoriatic dermatitis.
    [Journal of Investigative Dermatology]

    Abstract

    Inhibition of Bromodomain Extraterminal Histone Readers Alleviates Skin Fibrosis in Experimental Models of Scleroderma

    Investigators determined the antifibrotic efficacy and potential mechanisms of bromodomain and extraterminal domain proteins inhibition in systemic sclerosis.
    [JCI Insight]

    Full ArticlePress ReleaseGraphical Abstract

    Nuclear Focal Adhesion Kinase Induces APC/C Activator Protein CDH1-Mediated Cyclin-Dependent Kinase4/6 Degradation and Inhibits Melanoma Proliferation

    The authors found that focal adhesion kinase (FAK) played a key role in cell cycle progression potentially through regulation of cyclin-dependent kinase 4/6 protein expression and showed that FAK inhibition increased its nuclear localization and induced G1 arrest in B16F10 melanoma cells.
    [Journal of Biological Chemistry]

    Full Article

    Enhanced Expression of p21 Promotes Sensitivity of Melanoma Cells towards Targeted Therapies

    Researchers unraveled the role of the p53 target gene CDKN1A/p21 in the response of melanoma cells towards BRAF inhibitor.
    [Experimental Dermatology]

    AbstractFull Article
    As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.
    REVIEWS

    The Future of Targeted Kinase Inhibitors in Melanoma

    There is a future for targeted kinase inhibitors in melanoma: in new applications such as adjuvant or neoadjuvant therapy and in novel combinations with immunotherapies or other targeted therapies.
    [Pharmacology & Therapeutics]

    Full Article
    INDUSTRY AND POLICY NEWS

    Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

    Kezar Life Sciences, Inc. announced topline results from the PRESIDIO Phase II clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis.
    [Kezar Life Sciences, Inc.]

    Press Release
    FEATURED EVENT

    EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology

    November 10 -12, 2022
    Bordeaux, France

    > See All Events

    JOB OPPORTUNITIES

    Senior Research Technician – Skin Stem Cell Lab

    Howard Hughes Medical Institute – New York, New York, United States

    Research Assistant II – Melanoma Medical Oncology

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Fellow- Cutaneous T Cell

    City of Hope – Duarte, California, United States

    Field Medical Director – Oncology

    Pfizer – Remote

    Research Technician I-II – Skin Stem Cell Lab

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Dermal Cell News Twitter